ARCHIVES

BMS Control Of Billion-Dollar Taxol Market Facing Court Challeges By Competitors

This article is from The Cancer Letter archive.

Vol. 24 No. 21 | May 29, 1998

Download PDF Visit The Full Archive

Related Articles

Duke Tells ACS The Check for $437,400 Is In The Mail

December 10, 2010

New Staff Proposals For Comprehensive Center Recognition Considered By NCAB

January 19, 1979

Dramatic responses to Iressa prompted further bench research. Results have limited clinical relevance, for now, but findings may explain failure of INTACT studies.

April 30, 2004

NCI Grants: BSA Subcommittee Recommends Review Of SPORE Program In Year 2000

June 26, 1998

Revlimid Also Demonstrates Response in Mantle Cell

July 29, 2011

Cooperative Group Chairman Objects “Personal” Comments, Other Deficiencies In Peer Review

January 16, 1981